EAU 2026: PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMRI: A Multi-Center, Phase III, Randomized Trial
At EAU 2026, Dr. Buteau and colleagues aimed to demonstrate that 68Ga-PSMA-11 PET/CT could reduce patients requiring biopsy and limit biopsy to targeted cores, without significantly decreasing significant prostate cancer diagnosis. Significant prostate cancer was defined as Gleason score 3+4 (≥10% pattern…